Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)

NCT00255034 · clinicaltrials.gov ↗
PHASE4
Phase
TERMINATED
Status
146
Enrollment
INDUSTRY
Sponsor class

Stopped Recruitment targets were unachievable in the currently available population.

Conditions

Interventions

Sponsor

Merck Sharp & Dohme LLC